Plus   Neg

Regeneron Pharma Announces Positive Phase 2 Results In Rare Blood Disorder

Regeneron Pharmaceuticals Inc. (REGN) announced data from the pozelimab Phase 2 clinical program in paroxysmal nocturnal hemoglobinuria or PNH, validating the weekly 800 mg subcutaneous dosing regimen, following an initial intravenous or IV loading dose. Pozelimab reduced the abnormal destruction of red blood cells, otherwise known as "hemolysis," with patients in the initial cohort achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase or LDH.

PNH is an ultra-rare, chronic, life-threatening disease where genetic mutations cause hemolysis, resulting in a range of symptoms including fatigue, shortness of breath and blood clots.

The results from initial 6-patient cohort showed pozelimab reduced lactate dehydrogenase to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria, utilizing a weekly subcutaneous dosing regimen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT